Introduction
Heart failure (HF) is a leading cause of mortality and hospitalizations in western countries, and represents a heavy financial burden for health care systems.
1,2 Current pharmacological treatments limit the deleterious activation of neurohormonal systems (including the renin-angiotensin and sympathetic systems) and reduce congestive symptoms but do not directly target derangements in key regulators of cardiac function at the myocardial level. The sarco/endoplasmic reticulum Ca 2+ ATPase (SERCA2a) regulates calcium re-uptake from the cytosol into the sarcoplasmic reticulum during excitation-contraction coupling in cardiomyocytes. 3 
Impaired Ca
2+ uptake secondary to decreased expression and activity of SERCA2a is a hallmark of HF, especially in the advanced stages of the disease. 4, 5 Restoration of SERCA2a by gene transfer improves the contractile function of cardiomyocytes derived from failing hearts as well as cardiac performance and survival in different experimental models of HF. 6, 7 The recent development of safe and cardiotropic vectors such as adeno-associated viruses (AAVs) has drawn attention towards gene transfer as a strategy for treating complex diseases such as HF. 8 In earlier studies (CUPID: Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease), it was reported that a single intracoronary infusion of a recombinant AAV serotype 1 (AAV1) expressing the SERCA2a gene was safe, feasible and associated with favourable effects in patients with HF. 9, 10 However, a larger placebo-controlled randomized outcome trial (Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b, CUPID-2) failed to demonstrate any clinical benefit of AAV1/SERCA2a in patients with advanced HF.
11
We report here the results of the AAV1/SERCA2a GENe Therapy Trial in Heart Failure (AGENT-HF) that investigated the effect of SERCA2a gene transfer on ventricular remodelling parameters using multimodality non-invasive cardiac imaging. In the AGENT-HF study, we used the same AAV1/SERCA2a vectors and placebo preparations as those used in the CUPID-2 study.
However, the AGENT-HF study was conducted as a separate study from the CUPID-2 study and was conducted in France, a country where no clinical centres participated in the CUPID studies. The AGENT-HF was designed as a companion study to the CUPID programme and none of the enrolled patients participated in the CUPID studies.
Methods

Study design
The AGENT-HF trial was a randomized, double-blind, placebocontrolled, phase 2 study conducted in three different cardiology Eligible patients were aged between 18 and 80 years and diagnosed with stable chronic HF [New York Heart Association (NYHA class III-IV)] due to ischaemic or non-ischaemic cardiomyopathy for at least 3 months before randomization. Patients had a left ventricular (LV) ejection fraction of ≤ 35% and were stable on an optimally tolerated stable medical treatment for at least 1 month before randomization. Exclusion criteria included the presence of atrial fibrillation without permanent ventricular pacing, cardiac surgery, or interventional procedure in the last 3 months, or intravenous diuretics or inotropes in the last 28 days before randomization. Other main exclusion criteria were severe renal failure (creatinine clearance <30 mL/min), recent infection, active neoplasia or chronic infectious disease.
Patients who met the entry criteria were enrolled and screened for the presence of anti-AAV1 neutralizing antibody titres. Patients with titres less than 1:2 (or equivocal titres) were further proposed for participation and randomization.
Procedures and randomization
All identified participants were admitted to the Pitié-Salpêtrière Hospital for baseline evaluations including cardiac computed tomography (CCT), echocardiography, measurement of O 2 consumption, and blood sampling. The following day, patients were scheduled for coronary angiography and infusion. Patients were randomly assigned (1:1) to receive either 1 × 10 13 DNase-resistant particles of AAV1/SERCA2a or placebo (same solution as the one in which AAV1/SERCA2a is diluted). Randomization was stratified based on the origin of HF (ischaemic vs. non-ischaemic). AAV1/SERCA2a and placebo vials were supplied by Celladon Inc. (La Jolla, CA, USA). Both the investigative product and the placebo were clear and colourless liquids and could not be visually distinguished, ensuring that all patients, physicians, and outcome assessors were blinded to treatment assignment. Infusion was tailored to the patient's coronary anatomy as previously described in the CUPID trials. 10, 11 Briefly, administration of the product was performed by slow anterograde coronary infusion (20 min) with different scenarios to achieve homogeneous delivery to the myocardium. Infusion of the product was started 10-25 min after intravenous nitroglycerin infusion in order to enhance uptake of AAV1/SERCA2a in cardiomyocytes by increasing vasodilation of the capillary bed as shown in animal models. 12 The investigational product or placebo was given once to each patient. After a 24 h observation period after infusion, patients were discharged and entered the 12 month active observation period (with visits at 1, 3, 6, 9, and 12 months). At 6 and 12 months after administration, patients were hospitalized in La Pitié-Salpêtrière Hospital for cardiac evaluations as performed at baseline (i.e. immediately before infusion).
Study endpoints
The primary efficacy endpoint was based on the comparison of absolute changes in LV end-systolic volumes (LVESV) from baseline to 6 months between the AAV1/SERCA2a and placebo groups. LVESV was measured by CCT. All acquisitions were made on a dual source multi-detector scanner (Siemens, SOMATOM Definition Flash, Erlangen, Germany) with automated radiation dose modulation optimized for patient morphology. A standardized triple-phase contrast protocol was used in all patients: 70 mL of iomeprol followed by 50 mL of a 50:50 mix of iomeprol and saline and 50 mL saline flush. Scan parameters were retrospectively ECG-gated helicoidal acquisition using 128 × 0.6 mm collimation, tube voltage 120 mV, 200-350 mA range adjusted (CARE-Dose). Twenty phases of axial data were reconstructed from beginning to end of the cardiac cycle in 5% intervals. Left ventricular volumes were measured by an expert reader blinded to clinical history using a semi-automated segmentation method based on 3D Hounsfield-unit-related endocardial and epicardial contour detection (SyngoVia cardiac CT module, Siemens, Erlangen, Germany). Minor manual adjustments were made when necessary. The position of the mitral valve plane was carefully checked and LV volumes included the outflow tract. The end-diastolic and end-systolic time frames were selected on the basis of the 20 point volume-time curve. End-diastolic, end-systolic volumes, and LV mass were recorded and indexed to body surface area. Left ventricular ejection fraction was calculated.
Other endpoints included changes in CCT-measured LV enddiastolic volume, ejection fraction, echocardiography, peak (maximum rate of oxygen consumption), and NT-proBNP. Transthoracic echocardiography was performed using a Vivid9 equipped with a M5S convex transducer (GE Healthcare, Horten, Norway) by two different expert physicians, blinded to clinical and biological data. All examinations were analysed off-line with the use of a standard commercially available software (EchopacPC, GE-Vingmed-Ultrasound ® , Horten, Norway). All measurements were averaged over three to six cardiac cycles.
The following measurements were performed according to current guidelines. 13 Left atrium maximal volume was measured in two-dimensional mode at the end of ventricular systole just before opening of the mitral valve from apical four-and two-chamber views. Left ventricular volumes and LV ejection fraction were measured using the biplane Simpson method and cardiac index derived from aortic time-velocity integration, heart rate, and aortic outflow tract diameter. Measurements were indexed to body surface area as appropriate. Trans-mitral E wave velocity (E) was determined by Doppler echocardiography. Using tissue-Doppler data, we acquired e ′ , the mitral annular early diastolic velocity, on the four-chamber apical view, at septal level. Septal E/e ′ , rather than lateral E/e ′ , was then calculated and considered as a surrogate of LV filling pressure. 14 Global LV longitudinal strain (GLS) was measured off-line and blinded by one expert cardiologist. GLS was assessed on LV apical four-, three-and two-chamber-view images with speckle-tracking analysis.
Safety was assessed in all patients who received treatment with AAV1/SERCA2a or placebo. Safety endpoints included incidence and severity of clinical adverse events, monitoring of liver and renal markers, and monitoring of implantable cardioverter-defibrillator recordings. An independent data monitoring committee was responsible for monitoring the safety of the study. Finally, tissue samples were collected for patients treated with cardiac transplantation or mechanical circulatory support device during the study period or follow-up. To study the persistence of the transferred gene, quantitative polymerase chain reaction (qPCR) analysis (AltheaDx, Inc., San Diego, CA, USA) was performed. A TaqMan qPCR assay was developed to detect and quantify a specific sequence unique to AAV1/SERCA2a. The assay amplifies a 107 nucleotide sequence of the SERCA2 gene present in the AAV vector. The number of copies of AAV1/SERCA2a detected in up to 1 μg of genomic DNA extracted from each tissue was quantified using serial dilutions of a plasmid containing the target sequences as standards. 
Statistical analysis
Based on the results observed in the CUPID-1 trial, 10 we anticipated that LVESV would improve in the AAV1/SERCA2a group by 10 mL while it would deteriorate by 18 mL in the placebo group. This led to an estimated difference of 28 mL in the absolute changes in LVESV from baseline to 6 months between the AAV1/SERCA2a and placebo groups. With a standard error of 30 mL, a power of 80% and an alpha-error risk of 0.05, we estimated that 20 patients per group were needed. We then anticipated a 10% rate of death or heart transplantation in the 6 
Role of the funding source
This research was an investigator-initiated study that was supported in part (60%) by the French Ministry of Health (PHRC-N, AOM09191) and the Celladon Corporation (La Jolla, CA, USA). The funders of the study had no role in study design, data collection, data analysis, or writing of the report. Members of the steering committee had full access to all the data in the study and all authors had final responsibility for the decision to submit for publication.
Results
As the CUPID-2 outcome trial showed neutral results, 11 Celladon leadership decided on May 2015 to suspend enrolment in all clinical trials involving AAV1/SERCA2a, including the AGENT-HF trial. Consequently, all inclusions and administrations were stopped at that time but evaluations and follow-up were pursued for all patients that were already randomized. Figure 1 shows the trial profile at the time of termination. After screening on electronic medical records, 39 patients were enrolled and screened for anti-AAV1 neutralizing antibodies. Twenty-four patients (61.5%) showed high titres and could not participate further in the study. Fifteen patients were proposed for infusion of which, at the time of premature termination, nine were randomized with five patients infused with AAV1/SERCA2a and four with placebo.
Baseline characteristics were similar between groups (Table 1) , especially in terms of LV ejection fraction, haemodynamic profile and peak VO 2 max that were typical of patients with advanced HF. The origin of HF was ischaemic for half of the overall patients, but 60% in the AAV1/SERCA2a group and 25% in the placebo group. All patients received an optimal medical treatment for HF and about 80% had an implantable cardioverter-defibrillator. AAV1/SERCA2a
. or placebo infusions were performed in all patients without any serious adverse effects. The absolute and relative changes in LVESV (primary endpoint) are reported in Table 2 . In the placebo group, LVESV increased (median 3.5 mL) representing a 1.6% increase over the study period. However, LVESV was also increased in the AAV1/SERCA2a group (median 13 mL; relative increase of 4.4%). There was no significant difference between groups (mean difference of 11.4 mL, P = 0.74, Figure 2 ). Echocardiography similarly showed no improvement in either systolic or diastolic parameters in patients treated with AAV1/SERCA2a ( Table 3) . Similar trends were also observed for the main secondary endpoints (Table 4) , including cardiac remodelling parameters measured by CCT, biomarkers, and VO 2 max.
Finally, there were no differences between groups in clinical outcomes during the 12 month study period (Supplementary material online, Figure S1 ). During the long-term follow-up, a cardiac tissue sample (from one region) was obtained for one of the patients treated with AAV1/SERCA2a as the native heart became available at the time of cardiac transplantation (at Month 18 after administration). A qPCR assay for AAV1/SERCA2a DNA was performed as previously established in the CUPID-1 trial. However, the assay failed to detect the presence of AAV1/SERCA2a.
Discussion
The AGENT-HF clinical trial was designed as a companion study to the CUPID programme to specifically determine the effect of SERCA2a gene transfer on cardiac remodelling parameters. The AGENT-HF study represents the fourth gene therapy clinical trial in HF patients and was designed to be separate from the CUPID-2 study. However, we used the same AAV1/SERCA2a vector preparations as those used in the CUPID-2 study. Recruitment of the AGENT-HF study was prematurely interrupted following the neutral results of the CUPID-2 outcome study 11 but the AGENT-HF study also failed to show any trend for improvement of any cardiac remodelling parameters following AAV1/SERCA2a administration. The AGENT-HF study was initiated as the CUPID-1 study showed an improvement in LVESV (a secondary prospectively defined endpoint) in patients receiving AAV1/SERCA2a compared with placebo (−9.6 ± 27.5 mL vs. 18.2 ± 39.4 mL, respectively, P = 0.057).
10 Noteworthy, the number of infused patients was also small in the CUPID-1 study (25 infused with AAV1/SERCA2a vs. 14 placebo) and the effect was seen in the group of nine patients receiving the highest dose, which was the same dose as the one used in the AGENT-HF study. As a consequence, the AGENT-HF study failed to reproduce the beneficial effects observed in the CUPID-1 study and is more coherent with the neutral effect observed in the CUPID-2 outcome study.
10,11
Three main reasons could explain these divergent results. First, both the CUPID-1 and AGENT-HF studies were phase II exploratory studies conducted in a small number of patients. Because of premature termination, the AGENT-HF was underpowered to demonstrate an effect of AAV1/SERCA2a. The divergent results between both studies thus emphasize the need for caution in interpreting data from such small-scale studies. Second, morphological cardiac evaluations were performed with CCT in the AGENT-HF vs. echocardiography in CUPID-1.
10 Multimodality non-invasive cardiac imaging has been consistently shown as a more reliable method to evaluate cardiac volumes and function. 15, 16 There is, however, a risk that the end phase of the cardiac cycle is not properly captured because of a limited temporal resolution, a problem that can be overcome by the use of a multi-detector system as in our study. In addition, the CCT results were consistent with the ones obtained with echocardiography as well as with the other secondary endpoints.
Third, the vector used in the AGENT-HF was the same as the one used in the CUPID-2 trial but was different from the one used in the CUPID-1 trial due to a different manufacturing process. Notably, the proportion of empty viral capsid was lower (25%) in CUPID-2 and AGENT-HF vs. CUPID-1 (75% empty capsids).
11
The addition of empty capsids to full vector formulation has been recently shown to absorb pre-existing humoral immunity and therefore enhance the transduction efficiency after systemic delivery. 17 In line with this assumption, there was no detection of
